Virtual Tumor Board: Treating EGFR NSCLC After TKI Resistance
Feb 11, 2025•46 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
In this episode of Lung Cancer Considered, host Dr. Stephen Liu moderates a Virtual Tumor Board case involving drug resistance in EGFR mutant NSCLC. This discussion takes the listener through the treatment of EGFR mutant NSCLC after acquired resistance to osimertinib.
Guest: Dr. Yasushi Goto from National Cancer Center, Japan in Tokyo
Guest: Dr. Rachel Sanborn, the Earle A. Chiles Research Institute of the Providence Cancer Institute in Portland, Oregon
For the best experience, listen in Metacast app for iOS or Android